Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL)

What is it about?

In the Indian subcontinent, due to lack of stringent surveillance and lack of public awareness, prostate cancer is detected only when patients become symptomatic and often present at an advanced stage to the hospital/oncologist. Most patients on evaluation are diagnosed to have High Risk or Node-Positive or metastatic disseminated disease.

Our ongoing non-inferior, multicentre, phase III randomized trial is accruing patients with high risk and node-positive prostate cancer and randomizing them over two treatment schedules of moderate hypofractionation and extreme hypofractionation.

The trial aims to establish a therapeutically efficacious and cost-efficient modality for high risk and node-positive prostate cancer with an acceptable toxicity profile which could possibly have tremendous implications in terms of treating more patients, reduced expenditure for the healthcare system and patients alike.

Featured Image